Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path ...
Years after the first reports of Havana Syndrome emerged, U.S. officials have obtained and are testing a device that could ...
Individuals who struggle to complete tasks (at home, school, or the workplace) may not have a problem with executive function ...
During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...
Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.
4d
Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference
CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio ...
SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing of the first participant in the Phase 1b ...
About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...
Funding supports safety studies, manufacturing and clinical planning needed before applying to test the treatment in patients ...
The program will draw participants from a range of high schools across San Diego County, including schools that serve ...
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive neurodegenerative disorder caused by a CAG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback